12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Cellmid preclinical data

In a mouse model of diabetic nephropathy, 2 of Cellmid's MK-Abs significantly reduced glomerular sclerosis (<20% vs. 48%, p<0.01) and interstitial volume (12% vs. 35%, p<0.01)...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >